Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Using Dose Titration to Resolve Accelerated Male-Pattern Hair Loss on Testosterone Cypionate

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Label on hair / "Male pattern of baldness" is a listed skin reaction [1]
  • Labeled dose / 50 to 400 mg every 2 to 4 weeks; deep gluteal intramuscular injection, not intravenous [1]
  • Half-life / About 8 days after intramuscular injection [1]
  • Transgender men review / Alopecia continues to develop after 1 year of testosterone therapy [3]
  • Drugs tested for androgenetic alopecia / Minoxidil and finasteride are FDA-approved and beat placebo in a meta-analysis [4]

What does the label say about hair?

The Depo-Testosterone prescribing information lists "male pattern of baldness" under skin and appendages reactions, with hirsutism, seborrhea and acne, and gives no incidence figure for any of the reactions in that list [1]. It is a listed adverse reaction of treatment, not an approved use, and no dose or blood level is named as the point where it starts [1].

Labeled replacement dosing is 50 to 400 mg every 2 to 4 weeks, deep in the gluteal muscle, never intravenously, and the label states that dosage is adjusted according to the patient's response and the appearance of adverse reactions [1]. Those instructions set no hair-specific dose, interval or hormonal target [1].

Why the injection schedule gets discussed

Testosterone cypionate is an ester of testosterone in oil. Injected into muscle it is absorbed slowly from the lipid phase, which is why the label allows intervals of two to four weeks, and its half-life by that route is about eight days [1]. The label says that in many tissues the activity of testosterone appears to depend on reduction to dihydrotestosterone (DHT) [1]. DHT is the testosterone metabolite whose effects on androgen-sensitive follicles produce hair thinning in androgenetic alopecia, a pattern that begins with bitemporal recession and continues with vertex thinning in men [2].

What has been measured in men on testosterone

A 2017 review of testosterone therapy in transgender men listed alopecia among the undesired effects and noted that alopecia continues to develop past one year of treatment [3]. That describes hair loss progressing during continuing therapy; it is not a comparison of doses, intervals or products.

If hair keeps thinning, what has been tested?

Minoxidil and finasteride are the FDA-approved drugs for androgenetic alopecia, and a meta-analysis of randomized trials found both superior to placebo for hair density, thickness or growth [4]. In a 24-week randomized trial of 458 men with androgenetic alopecia, a topical finasteride spray raised target-area hair count by 20.2 hairs versus 6.7 with placebo (P<0.001) [5]. Dutasteride has trial evidence in this condition but is not an approved treatment for it [6]. These trials enrolled men with androgenetic alopecia, not men on testosterone cypionate.

Frequently asked questions

Does the testosterone cypionate label list hair loss as a side effect?
Yes. 'Male pattern of baldness' appears among skin and appendages reactions in the Depo-Testosterone prescribing information, alongside hirsutism, seborrhea and acne. That list gives no incidence figure for any of the reactions [1].
Is there a labeled dose that spares hair?
No hair-specific dose appears in the label. Labeled replacement dosing is 50 to 400 mg every 2 to 4 weeks by deep gluteal intramuscular injection, and the label says dosage is adjusted according to the patient's response and the appearance of adverse reactions [1].
Is there a testosterone or DHT level that protects hair?
The label sets no DHT target. Dose adjustment is described in terms of response and adverse reactions [1].
What if the shedding does not follow a male pattern?
Male-pattern loss begins with bitemporal recession and continues with vertex thinning, and scalp dermoscopy is used to confirm the diagnosis and distinguish it from other hair-loss conditions [2]. A different pattern raises a different diagnostic question.

References

  1. U.S. National Library of Medicine, DailyMed. Depo-Testosterone (cypionate) intramuscular, Pharmacia & Upjohn/Pfizer (testosterone cypionate) prescribing information. Depo-Testosterone (cypionate) intramuscular, Pharmacia & Upjohn/Pfizer (testosterone cypionate) label
  2. Piraccini BM, Alessandrini A. Androgenetic alopecia. G Ital Dermatol Venereol. 2014;149(1):15-24. Androgenetic alopecia
  3. Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017;5(4):301-311. Testosterone therapy for transgender men
  4. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis
  5. Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial
  6. Arif T, Dorjay K, Adil M, Sami M. Dutasteride in Androgenetic Alopecia: An Update. Curr Clin Pharmacol. 2017;12(1):31-35. Dutasteride in Androgenetic Alopecia: An Update
Evidence overview for Using Dose Titration to Resolve Accelerated Male-Pattern Hair Loss on Testosterone Cypionate